Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proinflammatory cytokines – indirect pathway-level modulation is a therapeutic strategy focused on regulating the intracellular signaling networks that govern the production and activity of multiple inflammatory mediators (NCBI, 2017: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542673/). Rather than targeting a single cytokine like TNF-alpha or IL-6 with a}
Inhibition of intracellular signaling nodes such as Janus kinases (JAKs), the IKK complex, or phosphodiesterases, and the modulation of transcription factors like NF-kappaB or the glucocorticoid receptor to suppress the transcription and translation of multiple proinflammatory cytokine genes.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proinflammatory cytokines – indirect pathway-level modulation.